Literature DB >> 18344056

CSF B--lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis.

Unn Ljøstad1, Ase Mygland.   

Abstract

Recent studies have suggested a diagnostic role of the B-lymphocyte attracting chemokine (CXCL13) in the cerebrospinal fluid (CSF) in Lyme neuroborreliosis (LNB). Our aim was to evaluate diagnostic accuracy of CSF CXCL13 in a cohort of 59 consecutive patients referred to hospital for suspected LNB. Thirty-seven patients were classified as definite LNB and used as the reference standard. Seven were classified as probable, and seven as possible LNB. Eight patients did not fulfil case definitions and were used as controls. At presentation, CSF CXCL13 was elevated in all patients with definite LNB, as compared to a positive CSF B. burgdorferi (Bb) antibody index (AI) in 33 of 37. Pre-treatment sensitivity of elevated CSF [corrected] Bb Al [corrected] was 100 % (95 % CI = 91-100) and 89 % [corrected] (95 % CI = 75-96) respectively (p = 0.053). Among the eight control patients, CSF CXCL13 was normal in five and only slightly elevated in three, and Bb AI was negative in five. Specificity of CSF CXCL13 and Bb AI was similar 63 % (95 % CI = 31-86) (p = 1.0).CSF CXCL13 was elevated in 6/7 patients with probable LNB and 3/7 patients with possible LNB. Bb AI was negative in all these 14 patients. An additional control group consisted of 31 patients with multiple sclerosis (MS), 11 with non-inflammatory neurological diseases, and ten with verified non-Lyme meningitis and high CSF cell count. CSF CXCL13 was slightly elevated in 15 MS patients, and in nine meningitis patients. Mean CSF CXCL13 was higher in definite LNB (3524 ng/g CSF protein) than in MS (27 ng/g) and non-Lyme meningitis (23 ng/g) (p < 0.001). Four months post-treatment CSF CXCL13 was normalized in 82 % of patients with definite LNB, as compared to a negative Bb AI in 10 % (p < 0.001).CSF CXCL13 may be a useful supplement in early diagnosis of acute LNB.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18344056     DOI: 10.1007/s00415-008-0785-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

1.  The immune response at onset and during recovery from Borrelia burgdorferi meningoradiculitis.

Authors:  Sabine Cepok; Dun Zhou; Friederike Vogel; Berit Rosche; Verena Grummel; Norbert Sommer; Bernhard Hemmer
Journal:  Arch Neurol       Date:  2003-06

Review 2.  European Union Concerted Action on Risk Assessment in Lyme Borreliosis: clinical case definitions for Lyme borreliosis.

Authors:  G Stanek; S O'Connell; M Cimmino; E Aberer; W Kristoferitsch; M Granström; E Guy; J Gray
Journal:  Wien Klin Wochenschr       Date:  1996-12-13       Impact factor: 1.704

3.  Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-05-02

4.  The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis.

Authors:  T A Rupprecht; H W Pfister; B Angele; S Kastenbauer; B Wilske; U Koedel
Journal:  Neurology       Date:  2005-08-09       Impact factor: 9.910

5.  Intrathecal immune response in neuroborreliosis: importance of cross-reactive antibodies.

Authors:  R Kaiser
Journal:  Zentralbl Bakteriol       Date:  1995-04

6.  Borrelia garinii induces CXCL13 production in human monocytes through Toll-like receptor 2.

Authors:  Tobias A Rupprecht; Carsten J Kirschning; Bernadette Popp; Stefan Kastenbauer; Volker Fingerle; Hans-Walter Pfister; Uwe Koedel
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

Review 7.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet
Journal:  BMJ       Date:  2003-01-04

8.  Borrelia burgdorferi-specific intrathecal antibody production in neuroborreliosis: a follow-up study.

Authors:  S Hammers-Berggren; K Hansen; A M Lebech; M Karlsson
Journal:  Neurology       Date:  1993-01       Impact factor: 9.910

9.  Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis.

Authors:  H Tumani; G Nölker; H Reiber
Journal:  Neurology       Date:  1995-09       Impact factor: 9.910

10.  Analysis of the intrathecal immune response in neuroborreliosis to a sonicate antigen and three recombinant antigens of Borrelia burgdorferi sensu stricto.

Authors:  R Kaiser; S Rauer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

View more
  26 in total

1.  [CXCL13: a biomarker for acute Lyme neuroborreliosis: investigation of the predictive value in the clinical routine].

Authors:  T A Rupprecht; C Lechner; H Tumani; V Fingerle
Journal:  Nervenarzt       Date:  2014-04       Impact factor: 1.214

2.  MyD88- and TRIF-independent induction of type I interferon drives naive B cell accumulation but not loss of lymph node architecture in Lyme disease.

Authors:  Christine J Hastey; Jennine Ochoa; Kimberley J Olsen; Stephen W Barthold; Nicole Baumgarth
Journal:  Infect Immun       Date:  2014-01-22       Impact factor: 3.441

3.  Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid.

Authors:  N D van Burgel; F Bakels; A C M Kroes; A P van Dam
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

4.  [CXCL-13 as a biomarker in the diagnostics of neuroborreliosis].

Authors:  C Waiß; W Kindler; B Ströbele; C Aspöck; S Oberndorfer
Journal:  Nervenarzt       Date:  2017-06       Impact factor: 1.214

5.  CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5.

Authors:  Bao-Chun Jiang; De-Li Cao; Xin Zhang; Zhi-Jun Zhang; Li-Na He; Chun-Hua Li; Wen-Wen Zhang; Xiao-Bo Wu; Temugin Berta; Ru-Rong Ji; Yong-Jing Gao
Journal:  J Clin Invest       Date:  2016-01-11       Impact factor: 14.808

6.  Neuroborreliosis.

Authors:  John J Halperin
Journal:  J Neurol       Date:  2016-11-24       Impact factor: 4.849

7.  CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation.

Authors:  Jukka Hytönen; Elisa Kortela; Matti Waris; Juha Puustinen; Jemiina Salo; Jarmo Oksi
Journal:  J Neuroinflammation       Date:  2014-06-11       Impact factor: 8.322

Review 8.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

Review 9.  Lyme neuroborreliosis-epidemiology, diagnosis and management.

Authors:  Uwe Koedel; Volker Fingerle; Hans-Walter Pfister
Journal:  Nat Rev Neurol       Date:  2015-07-28       Impact factor: 42.937

Review 10.  [Neuroborreliosis].

Authors:  R Kaiser; V Fingerle
Journal:  Nervenarzt       Date:  2009-10       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.